- Pregnant women are excluded from this study because CCI-779 (temsirolimus) is an agent with the potential for teratogenic or abortifacient effects; nursing women are also excluded, as there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CCI-779 (temsirolimus); breastfeeding should be discontinued if the mother is treated with CCI-779 (temsirolimus)